Comment on ‘Clinical Significance of BRAF Non-V600e Mutations on the Therapeutic Effects of Anti-Egfr Monoclonal Antibody Treatment in Patients With Pretreated Metastatic Colorectal Cancer: The Biomarker Research for Anti-Egfr Monoclonal Antibodies by Comprehensive Cancer Genomics (BREAC) Study’
British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0012-2
Full Text
Open PDFAbstract
Available in full text
Date
March 22, 2018
Authors
Publisher
Springer Science and Business Media LLC